<DOC>
	<DOCNO>NCT01838369</DOCNO>
	<brief_summary>The purpose study investigate effect BI-505 tumor burden patient diagnose smolder multiple myeloma .</brief_summary>
	<brief_title>A Phase II Study BI-505 Smoldering Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Diagnosis Smoldering multiple myeloma base International Myeloma Working Group criterion : Serum Mprotein great equal 3 g/dL and/or bone marrow plasma cell great equal 10 percent . Absence endorgan damage lytic bone lesion , anemia , hypercalcemia renal failure attribute plasma cell proliferative disorder . Male female , 18 year old . Eastern Cooperative Oncology Group ( ECOG ) Performance status 01 . Patients diagnosis symptomatic multiple myeloma clinical suspicion ongoing progression symptomatic multiple myeloma . Prior current treatment proven potential impact myeloma cell proliferation survival ( include conventional chemotherapy , biological therapy , immunomodulatory drug , proteasome inhibitor ) , judge Investigator . Severe condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>